登录获取学术和非营利定价

世界*实验材料供应商BioXCell正式授权为其中国代理，BioXCell在一直是行业的标杆,一直为广大科研客户提供zui为的产品和服务,一直秉承为中国科研客户带来的产品，的服务，签约BioXCell就是为了给广大科研客户带来更加完善的产品和服务,您的满意将是我们zui大的收获

BioXCell中国代理,BioXCell上海代理，BioXCell北京代理，BioXCell广东代理，BioXCell江苏代理BioXCell湖北代理,BioXCell天津,BioXCell黑龙江代理,BioXCell内蒙古代理,BioXCell吉林代理,BioXCell福建代理,BioXCell江苏代理,BioXCell浙江代理,BioXCell四川代理,

Bio X Cell是一家位于美国新罕布什尔州West Lebanon的生产用于生物医学研究的高品质、散装（毫克至克级）单克隆抗体的生物技术公司，该公司专业供应高纯度、低内毒素的抗体、重组蛋白、融合蛋白的高科技生物技术公司，供应规模可从毫克至克。因该公司具有超过15年的单克隆抗体和重组蛋白的定制生产经验，其研发的抗体采用先进的细胞培养生物反应器技术从培养组织中提取，并通过亲和层析纯化，进而保证了其高纯度（>95％），低内毒素（<2 EU /毫克）特性，并且不添加防腐剂或稳定剂，因而特别适合科研、制药和诊断行业的临床前研究。如客户机研究人员使用本公司抗体（需在销售后六个月内，并遵循本公司推荐的试剂储存方式）不能得到可出版的效果，本公司承诺将全部更换产品。而该公司生产的重组蛋白采用的发酵和纯化技术，确保得到高活性和高纯度的重组蛋白，目前Bio X cell公司具有所有主要表达系统进行重组蛋白的表达，包括：CHO、NSO、293、昆虫细胞、大肠杆菌和酵母表达系统，并且采用的发酵技术，如搅拌槽内发酵和Wavebag系统，生产能力范围从5-500L。BioXCell还有相应的FC-region，his标签，flag标签和GST亲和标签的重组蛋白的纯化设备和纯化经验。。此外，BioXCell提供相应的发酵和纯化定制服务，根据客户要求提供单克隆抗体杂交瘤细胞以及来源于哺乳动物，昆虫和微生物表达系统如CHO，293，杆状病毒ES，酵母，大肠杆菌等重组蛋白的发酵和纯化服务。

InVivoMAb anti-mouse PD-1 (CD279)

CloneRMP1-14

Catalog # BE0146

Category InVivoMab Antibodies

The RMP1-14 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by thePdcd1gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally,Pdcd1mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments. Like the J43 antibody the RMP1-14 antibody has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1.